Houman Vosoghi, MD
Glaucoma Specialist · Westlake Village, CANPI 1427279322
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $80,116 of the $118,908 with a category attached, or 67.4%. AbbVie accounts for 69.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $36,320 and has fallen 59.5% since, to $14,720 in 2025. Among glaucoma specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $323.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$83K
- Aerie Pharmaceuticals, Inc.$29K
- Alcon$5K
- Sun Pharmaceutical Industries Inc.$908
- Glaukos Corporation$393
- Amgen$156
- plus $769 from 11 others
What the payments were for
- Consulting fees$80,11667%
- Speaking & faculty fees$27,28923%
- Travel & lodging$5,5535%
- Food & beverage$5,9505%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 204 | $82,749 |
| Aerie Pharmaceuticals, Inc. | 37 | $29,302 |
| Alcon | 32 | $4,631 |
| Sun Pharmaceutical Industries Inc. | 53 | $908 |
| Glaukos Corporation | 5 | $393 |
| Amgen | 2 | $156 |
| Thea Pharma Inc. | 7 | $140 |
| Akorn Operating Company LLC | 8 | $136 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $119 |
| Novartis | 4 | $90 |
| Bausch & Lomb Americas Inc. | 4 | $80 |
| Akorn, Inc. | 3 | $70 |
| Sight Sciences, Inc. | 3 | $65 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $19 |
| Rxsight Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$118,908 in reported general payments places this provider in the 90th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 382 | $221,092 |
| RhopressaNetarsudil Mesylate | 300 | $184,721 |
| Alphagan PBrimonidine Tartrate | 317 | $161,092 |
| RocklatanNetarsudil Mesylat/Latanoprost | 86 | $70,241 |
| VyzultaLatanoprostene Bunod | 114 | $68,750 |
| RestasisCyclosporine | 42 | $66,622 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 242 | $55,844 |
| XiidraLifitegrast | 34 | $43,053 |
| CequaCyclosporine | 34 | $37,920 |
| TafluprostTafluprost/Pf | 128 | $31,095 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $19,757 |
| Cyclosporine | 30 | $18,597 |
| ZioptanTafluprost/Pf | 31 | $17,032 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 875 | $15,724 |
| Brimonidine Tartrate | 312 | $14,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan | $82,749 | $468,563783 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $29,302 | $254,961386 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $80 | $111,803148 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $908 | $37,92034 claims |
| Akorn, Inc.Zioptan | $70 | $17,03231 claims |
| Thea Pharma Inc.Iyuzeh | $140 | $8,74620 claims |
| AlconSimbrinza | $4,631 | $5,31322 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $119 | $3,15919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Westlake Village
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
- Philip NgaiWest Covina$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.